Want to see HK:6118 full AI Analyst Report?
6118 Stock Chart & Stats
HK$0.89
-HK$0.02(-3.39%)
At close: 4:00 PM EST
HK$0.89
-HK$0.02(-3.39%)
Day’s Range― - ―
52-Week RangeHK$0.65 - HK$1.60
Previous CloseN/A
Volume4.00K
Average Volume (3M)695.30K
Market Cap
HK$363.93M
Enterprise ValueHK$398.62M
Total Cash (Recent Filing)HK$276.59M
Total Debt (Recent Filing)HK$343.82M
Price to Earnings (P/E)9.3
Beta0.89
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding512,582,030
10 Day Avg. Volume1,360,300
30 Day Avg. Volume695,300
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.49
Price to Sales (P/S)0.26
P/FCF Ratio4.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Leverage And Sizable Equity BaseLower leverage and a sizable equity base increase financial flexibility and reduce solvency risk over the medium term. With debt-to-equity improved from ~0.64 to ~0.42 and stable assets (~2.1B), the company has structural capacity to fund operations, absorb shocks, or invest without excessive refinancing pressure.
Positive Operating And Free Cash Flow RecentlySustained positive OCF and FCF provide durable internal funding for capex, debt reduction, and potential shareholder returns. Recent OCF of ~128.2M and FCF ~99.7M signal improved conversion of earnings to cash, underpinning balance sheet strength and strategic optionality over the next several quarters.
Return To Profitability And Positive Earnings TrendRecovery from a 2023 loss to positive net income and resumed EBIT/EBITDA indicates fundamental operational improvement. A multi-year return to profitability creates a platform for margin stabilization, reinvestment in the business, and continued deleveraging if margins can be preserved or expanded.
Bears Say
Thin Margins And Low Returns On EquityLow net margin and ROE reflect limited ability to translate revenue into meaningful shareholder returns. Persistently thin profitability constrains reinvestment capacity and makes earnings vulnerable to cost or pricing pressure, reducing resilience and long-term capital efficiency unless margins improve materially.
History Of Volatile Cash FlowsA track record of multi-year swings into negative cash flow shows operating cash generation is not yet consistently durable. That volatility raises execution risk for funding growth, servicing debt, and maintaining capital expenditures, and increases reliance on good years to repair balance sheet metrics.
Choppy Revenue Trend And Modest Top-line GrowthIrregular revenue performance and only modest recent growth limit scale benefits and margin recovery prospects. Slow top-line expansion makes it harder to leverage fixed costs or invest in R&D and commercial expansion, constraining durable competitive progress in the medical devices industry.
Austar Lifesciences Ltd. News
6118 FAQ
What was Austar Lifesciences Ltd.’s price range in the past 12 months?
Austar Lifesciences Ltd. lowest stock price was HK$0.65 and its highest was HK$1.60 in the past 12 months.
What is Austar Lifesciences Ltd.’s market cap?
Austar Lifesciences Ltd.’s market cap is HK$363.93M.
When is Austar Lifesciences Ltd.’s upcoming earnings report date?
Austar Lifesciences Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 28 days.
How were Austar Lifesciences Ltd.’s earnings last quarter?
Austar Lifesciences Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.019 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.019.
Is Austar Lifesciences Ltd. overvalued?
According to Wall Street analysts Austar Lifesciences Ltd.’s price is currently Overvalued.
Does Austar Lifesciences Ltd. pay dividends?
Austar Lifesciences Ltd. pays a Notavailable dividend of HK$0.05 which represents an annual dividend yield of N/A. See more information on Austar Lifesciences Ltd. dividends here
What is Austar Lifesciences Ltd.’s EPS estimate?
Austar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Austar Lifesciences Ltd. have?
Austar Lifesciences Ltd. has 512,582,030 shares outstanding.
What happened to Austar Lifesciences Ltd.’s price movement after its last earnings report?
Austar Lifesciences Ltd. reported an EPS of HK$0.019 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Austar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in HK:6118
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Austar Lifesciences Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.89%
Trailing 12-Months
Company Description
Austar Lifesciences Ltd.
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland China. Its business activities are structured across six primary divisions: liquid and bioprocessing systems; controlled environment and automated monitoring systems; powder and solid material handling systems; Good Manufacturing Practice (GMP) adherence services; life science expendables; and the brokerage and supply of pharmaceutical machinery. The company's product portfolio is extensive, including systems for pharmaceutical water, liquid preparation, and bioprocessing; powder and solid processing units; clean utility infrastructure; and advanced cleanroom technology. They also supply automated control and monitoring systems, freeze-dryers, sterile filling equipment, and visual inspection apparatus. Furthermore, Austar provides products for pharmaceutical contamination control, aseptic packaging and containment, biosafety and lab animal equipment and consumables, single-use bioprocess components, and offers holistic laboratory setup solutions. Beyond its product offerings, Austar Lifesciences extends a wide array of professional services, such as design and engineering, quality risk management, expert consultation, research and development assistance, process optimization, and digitalization strategies. The company also offers post-sale support, on-site services, system upgrades, facility relocation guidance, and comprehensive asset management. Additionally, it serves as an agent and distributor for pharmaceutical equipment, providing associated assembly and pre-assembly services. Established in 1991, Austar Lifesciences Limited is headquartered in Shanghai, China.
Technical Analysis
Vincent Medical Holdings Limited
―
Suzhou Basecare Medical Corp. Ltd. Class H
―
Broncus Holding Corp.
―
Rainmed Medical Limited
―
Venus Medtech (Hangzhou), Inc. Class H
―